Bioceres Crop Solutions Corp.
BIOX
$5.19
$0.214.22%
| Weiss Ratings | BIOX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | D | |||
| Rating Factors | BIOX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Fair | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BIOX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.50 | |||
| Price History | BIOX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 18.22% | |||
| 30-Day Total Return | -24.23% | |||
| 60-Day Total Return | -20.03% | |||
| 90-Day Total Return | -25.64% | |||
| Year to Date Total Return | -22.77% | |||
| 1-Year Total Return | -59.92% | |||
| 2-Year Total Return | -55.79% | |||
| 3-Year Total Return | -64.45% | |||
| 5-Year Total Return | 10.19% | |||
| 52-Week High % Change | -63.11% | |||
| 52-Week Low % Change | 35.14% | |||
| Price | BIOX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $13.50 | |||
| 52-Week Low Price | $3.69 | |||
| 52-Week Low Price (Date) | Mar 04, 2025 | |||
| 52-Week High Price (Date) | Mar 08, 2024 | |||
| Valuation | BIOX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 312.30M | |||
| Enterprise Value | 603.53M | |||
| Price/Earnings (TTM) | 325.49 | |||
| Earnings Per Share (TTM) | 0.02 | |||
| Earnings Per Share Growth | -95.59% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.77 | |||
| Price/Book (Q) | 1.01 | |||
| Enterprise Value/Revenue (TTM) | 1.48 | |||
| Price | $5.19 | |||
| Enterprise Value/EBITDA (TTM) | 11.86 | |||
| Enterprise Value/EBIT | 18.45 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | BIOX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 63.17M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BIOX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 54 34 1486 1100 | |||
| Address | -- | |||
| Website | investors.biocerescrops.com/home/default.aspx | |||
| Country | Argentina | |||
| Year Founded | 2001 | |||
| Profitability | BIOX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 8.02% | |||
| Profit Margin | 0.36% | |||
| Management Effectiveness | BIOX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 2.47% | |||
| Return on Equity | 0.62% | |||
| Income Statement | BIOX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 407.73M | |||
| Total Revenue (TTM) | 407.73M | |||
| Revenue Per Share | $6.45 | |||
| Gross Profit (TTM) | 169.89M | |||
| EBITDA (TTM) | 50.89M | |||
| EBIT (TTM) | 32.71M | |||
| Net Income (TTM) | 1.50M | |||
| Net Income Avl. to Common (TTM) | 1.50M | |||
| Total Revenue Growth (Q YOY) | -23.90% | |||
| Earnings Growth (Q YOY) | -51.13% | |||
| EPS Diluted (TTM) | 0.02 | |||
| EPS Diluted Growth (Q YOY) | 35.29% | |||
| Balance Sheet | BIOX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 31.20M | |||
| Cash Per Share (Q) | $0.49 | |||
| Total Current Assets (Q) | 382.57M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 346.33M | |||
| Current Ratio (Q) | 1.325 | |||
| Book Value Per Share (Q) | $4.94 | |||
| Total Assets (Q) | 835.20M | |||
| Total Current Liabilities (Q) | 288.78M | |||
| Total Debt (Q) | 285.64M | |||
| Total Liabilities (Q) | 488.87M | |||
| Total Common Equity (Q) | 309.55M | |||
| Cash Flow | BIOX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -6.78M | |||
| Cash from Financing (TTM) | 3.91M | |||
| Net Change in Cash (TTM) | 4.77M | |||
| Levered Free Cash Flow (TTM) | -25.60M | |||
| Cash from Operations (TTM) | 5.67M | |||
